{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:55:51Z","timestamp":1781646951255,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science Foundation","award":["NSF-DMS-2052648"],"award-info":[{"award-number":["NSF-DMS-2052648"]}]},{"name":"National Science Foundation","award":["NSF-DMS-2052648"],"award-info":[{"award-number":["NSF-DMS-2052648"]}]},{"name":"National Science Foundation","award":["NSF-DMS-2052648"],"award-info":[{"award-number":["NSF-DMS-2052648"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Methicillin-resistant\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    (MRSA) increasingly undermines the effectiveness of topical fluoroquinolone monotherapy in ophthalmic infections. We present a theoretical evaluation of rotational fluoroquinolone therapy, in which moxifloxacin and trovafloxacin are alternated to enhance bacterial suppression and mitigate resistance. Experimental time-kill data were fit using Bayesian parameter estimation via Markov Chain Monte Carlo (MCMC) to derive drug-specific growth and kill parameters, which were integrated into spatiotemporal pharmacodynamic models. These models incorporate radial anterior chamber geometry, intraocular diffusion, and aqueous humor pharmacokinetics governed by a circadian clearance function. Structural docking simulations of topoisomerase IV mutants reveal that common resistance mutations disrupt moxifloxacin binding while preserving trovafloxacin affinity, supporting a collateral-sensitivity mechanism. Under high-resistance conditions, rotational therapy improves bacterial clearance compared to monotherapy by increasing heterogeneity in antimicrobial exposure fronts and reducing overall bacterial burden. By alternating fluoroquinolones with complementary resistance profiles, rotational therapy leverages physiological clearance rhythms and spatial drug gradients to enhance anterior-segment efficacy, providing a quantitative foundation for its use as a rational alternative to monotherapy in ocular MRSA management.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-30598-x","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:34:21Z","timestamp":1775039661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modeling rotational fluoroquinolone therapy as a novel treatment for ophthalmic MRSA infections"],"prefix":"10.1038","volume":"16","author":[{"given":"Alejandro","family":"Storper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlene","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"30598_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/pathogens7010009","volume":"7","author":"RJ O\u2019Callaghan","year":"2018","unstructured":"O\u2019Callaghan, R. J. The pathogenesis of Staphylococcus aureus eye infections. Pathogens 7, 9. https:\/\/doi.org\/10.3390\/pathogens7010009 (2018).","journal-title":"Pathogens"},{"key":"30598_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042437","volume":"8","author":"C-C Chuang","year":"2012","unstructured":"Chuang, C.-C. et al. Staphylococcus aureus ocular infection: Methicillin-resistance, clinical features, and antibiotic susceptibilities. PLoS ONE 8, e42437. https:\/\/doi.org\/10.1371\/journal.pone.0042437 (2012).","journal-title":"PLoS ONE"},{"key":"30598_CR3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jcrs.2008.01.016","volume":"34","author":"PA Asbell","year":"2008","unstructured":"Asbell, P. A., Sahm, D. F., Shaw, M. M. T., Draghi, D. C. & Brown, N. P. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005. J. Cataract Refract. Surg. 34, 814\u2013818. https:\/\/doi.org\/10.1016\/j.jcrs.2008.01.016 (2008).","journal-title":"J. Cataract Refract. Surg."},{"key":"30598_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ajo.2007.10.020","volume":"145","author":"VA Deramo","year":"2008","unstructured":"Deramo, V. A., Lai, J. C., Winokur, J., Luchs, J. & Udell, I. J. Visual outcome and bacterial sensitivity after methicillin-resistant Staphylococcus aureus\u2013associated acute endophthalmitis. Am. J. Ophthalmol. 145, 413\u2013417 (2008).","journal-title":"Am. J. Ophthalmol."},{"key":"30598_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ophtha.2011.08.038","volume":"119","author":"C-H Hsiao","year":"2012","unstructured":"Hsiao, C.-H. et al. Methicillin-resistant Staphylococcus aureus ocular infection: A 10-year hospital-based study. Ophthalmology 119, 522\u2013527. https:\/\/doi.org\/10.1016\/j.ophtha.2011.08.038 (2012).","journal-title":"Ophthalmology"},{"key":"30598_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jcrs.2006.02.021","volume":"32","author":"P Barry","year":"2006","unstructured":"Barry, P. et al. Escrs study of prophylaxis of postoperative endophthalmitis after cataract surgery: Case for a European multicenter study. J. Cataract Refract. Surg. 32, 407\u2013410. https:\/\/doi.org\/10.1016\/j.jcrs.2006.02.021 (2006).","journal-title":"J. Cataract Refract. Surg."},{"key":"30598_CR7","doi-asserted-by":"publisher","DOI":"10.5812\/jjm.35052","volume":"9","author":"SM Mahdiyoun","year":"2016","unstructured":"Mahdiyoun, S. M., Kazemian, H., Ahanjan, M., Houri, H. & Goudarzi, M. Frequency of aminoglycoside-resistance genes in methicillin-resistant Staphylococcus aureus (MRSA) isolates from hospitalized patients. Jundishapur J. Microbiol. 9, e35052. https:\/\/doi.org\/10.5812\/jjm.35052 (2016).","journal-title":"Jundishapur J. Microbiol."},{"key":"30598_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.5897\/JMA2014.0315","volume":"6","author":"ND Gade","year":"2014","unstructured":"Gade, N. D. & Qazi, M. S. Recent trend of aminoglycoside resistance among Staphylococcus aureus isolates in tertiary care hospital. J. Microbiol. Antimicrob. 6, 94\u201396. https:\/\/doi.org\/10.5897\/JMA2014.0315 (2014).","journal-title":"J. Microbiol. Antimicrob."},{"key":"30598_CR9","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012). Updated Mar 10 (2020)."},{"key":"30598_CR10","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2147\/OPTH.S12027","volume":"4","author":"LF Porter","year":"2010","unstructured":"Porter, L. F., Khan, R. U., Hannan, A. & Kelly, S. P. MRSA and cataract surgery - reflections for practice. Clin. Ophthalmol. 4, 1223\u20131227. https:\/\/doi.org\/10.2147\/OPTH.S12027 (2010).","journal-title":"Clin. Ophthalmol."},{"key":"30598_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1592\/phco.19.1.21.30507","volume":"19","author":"KW Garey","year":"1999","unstructured":"Garey, K. W. & Amsden, G. W. Trovafloxacin: an overview. Pharmacotherapy 19, 21\u201334. https:\/\/doi.org\/10.1592\/phco.19.1.21.30507 (1999).","journal-title":"Pharmacotherapy"},{"key":"30598_CR12","doi-asserted-by":"publisher","first-page":"74S","DOI":"10.1016\/S0002-9610(98)00224-4","volume":"176","author":"DJ Williams","year":"1998","unstructured":"Williams, D. J. & Hopkins, S. Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin. Am. J. Surg. 176, 74S-79S. https:\/\/doi.org\/10.1016\/S0002-9610(98)00224-4 (1998).","journal-title":"Am. J. Surg."},{"key":"30598_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1128\/AAC.44.3.802-805.2000","volume":"44","author":"D Hardy","year":"2000","unstructured":"Hardy, D., Amsterdam, D., Mandell, L. A. & Rotstein, C. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. Antimicrob. Agents Chemother. 44, 802\u2013805. https:\/\/doi.org\/10.1128\/AAC.44.3.802-805.2000 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30598_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1128\/AAC.37.2.366","volume":"37","author":"GM Eliopoulos","year":"1993","unstructured":"Eliopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J. & Moellering, R. C. J. In vitro activity of cp-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37, 366\u2013370. https:\/\/doi.org\/10.1128\/AAC.37.2.366 (1993).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30598_CR15","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1128\/AAC.41.5.1146","volume":"41","author":"HP Endtz","year":"1997","unstructured":"Endtz, H. P., Mouton, J. W., den Hollander, J. G., van den Braak, N. & Verbrugh, H. A. Comparative in vitro activities of trovafloxacin (cp-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Antimicrob. Agents Chemother. 41, 1146\u20131149. https:\/\/doi.org\/10.1128\/AAC.41.5.1146 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30598_CR16","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1128\/AAC.43.8.2000","volume":"43","author":"E Pestova","year":"1999","unstructured":"Pestova, E., Beyer, R., Cianciotto, N. P., Noskin, G. A. & Peterson, L. R. Contribution of topoisomerase iv and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob. Agents Chemother. 43, 2000\u20132004. https:\/\/doi.org\/10.1128\/AAC.43.8.2000 (1999).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30598_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2478\/v10007-010-0023-x","volume":"60","author":"M Jadrijevi\u0107-Mladar Takac","year":"2010","unstructured":"Jadrijevi\u0107-Mladar Takac, M. Effects of substituents on the nmr features of basic bicyclic ring systems of fluoroquinolone antibiotics and the relationships between nmr chemical shifts, molecular descriptors and drug-likeness parameters. Acta Pharmaceutica 60, 237\u2013254. https:\/\/doi.org\/10.2478\/v10007-010-0023-x (2010).","journal-title":"Acta Pharmaceutica"},{"key":"30598_CR18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1023\/A:1010741510046","volume":"46","author":"DA Lazarczyk","year":"2001","unstructured":"Lazarczyk, D. A., Goldstein, N. S. & Gordon, S. C. Case report: Trovafloxacin hepatotoxicity. Dig. Dis. Sci. 46, 925\u2013926. https:\/\/doi.org\/10.1023\/A:1010741510046 (2001).","journal-title":"Dig. Dis. Sci."},{"key":"30598_CR19","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Public health advisory: Trovafloxacin mesylate (trovan\u00ae) \u2014 risk of rare but serious hepatotoxicity. Tech. Rep., U.S. Food and Drug Administration (1999)."},{"key":"30598_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/jac\/44.2.193","volume":"44","author":"PJ van den Broek","year":"1999","unstructured":"van den Broek, P. J., Koot, T. G., van Strijen, E. & Mattie, H. Intracellular activity of trovafloxacin against Staphylococcus aureus. J. Antimicrob. Chemother. 44, 193\u2013199. https:\/\/doi.org\/10.1093\/jac\/44.2.193 (1999).","journal-title":"J. Antimicrob. Chemother."},{"key":"30598_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1128\/AAC.42.2.254","volume":"42","author":"GW Kaatz","year":"1998","unstructured":"Kaatz, G. W. et al. Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 42, 254\u2013256. https:\/\/doi.org\/10.1128\/AAC.42.2.254 (1998).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30598_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2165\/00003495-200059010-00010","volume":"59","author":"JA Barman Balfour","year":"2000","unstructured":"Barman Balfour, J. A. & Lamb, H. M. Moxifloxacin: A review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 59, 115\u2013139. https:\/\/doi.org\/10.2165\/00003495-200059010-00010 (2000).","journal-title":"Drugs"},{"key":"30598_CR23","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.survophthal.2005.07.001","volume":"50","author":"SM Robertson","year":"2005","unstructured":"Robertson, S. M. et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv. Ophthalmol. 50, S32\u2013S45. https:\/\/doi.org\/10.1016\/j.survophthal.2005.07.001 (2005).","journal-title":"Surv. Ophthalmol."},{"key":"30598_CR24","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/bph.13436","volume":"173","author":"GK Panicker","year":"2016","unstructured":"Panicker, G. K. et al. Detecting moxifloxacin-induced QTc prolongation in thorough QT and early clinical phase studies using a highly automated ECG analysis approach. Br. J. Pharmacol. 173, 1373\u20131380. https:\/\/doi.org\/10.1111\/bph.13436 (2016).","journal-title":"Br. J. Pharmacol."},{"key":"30598_CR25","doi-asserted-by":"publisher","unstructured":"Durairaj, C. Ocular pharmacokinetics. In: Whitcup, S. & Azar, D. (eds.) Pharmacologic Therapy of Ocular Disease, vol. 242 of Handbook of Experimental Pharmacology, https:\/\/doi.org\/10.1007\/164_2016_32 (Springer, Cham, 2016).","DOI":"10.1007\/164_2016_32"},{"key":"30598_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/archophthalmol.2011.45","volume":"129","author":"RE Fintelmann","year":"2011","unstructured":"Fintelmann, R. E. et al. Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures. Archives of Ophthalmology 129, 399\u2013402. https:\/\/doi.org\/10.1001\/archophthalmol.2011.45 (2011).","journal-title":"Archives of Ophthalmology"},{"key":"30598_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40123-021-00449-9","volume":"11","author":"PJM Bispo","year":"2022","unstructured":"Bispo, P. J. M., Sahm, D. F. & Asbell, P. A. A systematic review of multi-decade antibiotic resistance data for ocular bacterial pathogens in the United States. Ophthalmol. Ther. 11, 503\u2013520. https:\/\/doi.org\/10.1007\/s40123-021-00449-9 (2022).","journal-title":"Ophthalmol. Ther."},{"key":"30598_CR28","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/antibiotics10101203","volume":"10","author":"M Afzal","year":"2021","unstructured":"Afzal, M., Vijay, A. K., Stapleton, F. & Willcox, M. D. P. Susceptibility of ocular Staphylococcus aureus to antibiotics and multipurpose disinfecting solutions. Antibiotics (Basel) 10, 1203. https:\/\/doi.org\/10.3390\/antibiotics10101203 (2021).","journal-title":"Antibiotics (Basel)"},{"key":"30598_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4103\/0255-0857.83903","volume":"29","author":"S Sharma","year":"2011","unstructured":"Sharma, S. Antibiotic resistance in ocular bacterial pathogens. Indian J. Med. Microbiol. 29, 218\u2013222. https:\/\/doi.org\/10.4103\/0255-0857.83903 (2011).","journal-title":"Indian J. Med. Microbiol."},{"key":"30598_CR30","doi-asserted-by":"publisher","unstructured":"Oliveira, T. L. R. & d., Cavalcante, F. S., Chamon, R. C., Ferreira, R. B. R. & Santos, K. R. N. d. Genetic mutations in the quinolone resistance-determining region are related to changes in the epidemiological profile of Methicillin-resistant Staphylococcus aureus isolates. J. Glob. Antimicrob. Resist. 19, 236\u2013240. https:\/\/doi.org\/10.1016\/j.jgar.2019.05.026 (2019).","DOI":"10.1016\/j.jgar.2019.05.026"},{"key":"30598_CR31","doi-asserted-by":"crossref","unstructured":"Vestergaard, M., Frees, D. & Ingmer, H. Antibiotic resistance and the MRSA problem. Microbiol. spectr. 7, 10-1128 (2019).","DOI":"10.1128\/microbiolspec.GPP3-0057-2018"},{"key":"30598_CR32","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1128\/AAC.42.8.2122","volume":"42","author":"JE Fitzgibbon","year":"1998","unstructured":"Fitzgibbon, J. E., John, J. F., Delucia, J. L. & Dubin, D. T. Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 42, 2122\u20132124. https:\/\/doi.org\/10.1128\/AAC.42.8.2122 (1998).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30598_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3201\/eid0702.010239","volume":"7","author":"DC Hooper","year":"2001","unstructured":"Hooper, D. C. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. 7, 337\u2013341. https:\/\/doi.org\/10.3201\/eid0702.010239 (2001).","journal-title":"Emerg. Infect. Dis."},{"key":"30598_CR34","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1021\/acsinfecdis.3c00346","volume":"10","author":"AA Oviatt","year":"2024","unstructured":"Oviatt, A. A. et al. Interactions between gepotidacin and Escherichia coli gyrase and topoisomerase IV: Genetic and biochemical evidence for well-balanced dual-targeting. ACS Infect. Dis. 10, 1137\u20131151. https:\/\/doi.org\/10.1021\/acsinfecdis.3c00346 (2024).","journal-title":"ACS Infect. Dis."},{"key":"30598_CR35","doi-asserted-by":"publisher","unstructured":"Imamovic, L. & Sommer, M. O.\u00a0A. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci. Transl. Med. 5, 204ra132 https:\/\/doi.org\/10.1126\/scitranslmed.3006609 (2013).","DOI":"10.1126\/scitranslmed.3006609"},{"key":"30598_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.tim.2015.02.009","volume":"23","author":"C P\u00e1l","year":"2015","unstructured":"P\u00e1l, C., Papp, B. & L\u00e1z\u00e1r, V. Collateral sensitivity of antibiotic-resistant microbes. Trends Microbiol. 23, 401\u2013407. https:\/\/doi.org\/10.1016\/j.tim.2015.02.009 (2015).","journal-title":"Trends Microbiol."},{"key":"30598_CR37","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/msb.2013.57","volume":"9","author":"V L\u00e1z\u00e1r","year":"2013","unstructured":"L\u00e1z\u00e1r, V. et al. Bacterial evolution of antibiotic hypersensitivity. Mol. Syst. Biol. 9, 700 (2013).","journal-title":"Mol. Syst. Biol."},{"key":"30598_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009172","volume":"17","author":"R Roemhild","year":"2021","unstructured":"Roemhild, R. & Andersson, D. I. Mechanisms and therapeutic potential of collateral sensitivity to antibiotics. PLoS Pathogens 17, e1009172. https:\/\/doi.org\/10.1371\/journal.ppat.1009172 (2021).","journal-title":"PLoS Pathogens"},{"key":"30598_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jac\/43.suppl_2.31","volume":"43","author":"H Schedletzky","year":"1999","unstructured":"Schedletzky, H., Wiedemann, B. & Heisig, P. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus. J. Antimicrob. Chemother. 43, 31\u201337. https:\/\/doi.org\/10.1093\/jac\/43.suppl_2.31 (1999).","journal-title":"J. Antimicrob. Chemother."},{"key":"30598_CR40","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s10096-010-0964-5","volume":"29","author":"E Raineri","year":"2010","unstructured":"Raineri, E. et al. Rotation of antimicrobial therapy in the intensive care unit: impact on incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 29, 1015\u20131024 https:\/\/doi.org\/10.1007\/s10096-010-0964-5 (2010).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"30598_CR41","doi-asserted-by":"publisher","first-page":"7623","DOI":"10.1167\/iovs.12-12690","volume":"54","author":"CB Nau","year":"2013","unstructured":"Nau, C. B., Malihi, M., McLaren, J. W., Hodge, D. O. & Sit, A. J. Circadian variation of aqueous humor dynamics in older healthy adults. Investig. Ophthalmol. Vis. Sci. 54, 7623\u20137629 https:\/\/doi.org\/10.1167\/iovs.12-12690 (2013).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"30598_CR42","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.3390\/molecules25235662","volume":"25","author":"NG Bush","year":"2020","unstructured":"Bush, N. G., Diez-Santos, I., Abbott, L. R. & Maxwell, A. Quinolones: Mechanism, lethality and their contributions to antibiotic resistance. Molecules 25, 5662 https:\/\/doi.org\/10.3390\/molecules25235662 (2020).","journal-title":"Molecules"},{"key":"30598_CR43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0026-895X(24)12364-4","volume":"59","author":"J Kang","year":"2001","unstructured":"Kang, J., Wang, L., Chen, X.-L., Triggle, D. J. & Rampe, D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol. Pharmacol. 59, 122\u2013126. https:\/\/doi.org\/10.1016\/S0026-895X(24)12364-4 (2001).","journal-title":"Mol. Pharmacol."},{"key":"30598_CR44","unstructured":"American Academy of Ophthalmology Cornea\/External Disease PPP Panel. Bacterial keratitis preferred practice pattern\u00ae (2019). Updated 2023."},{"key":"30598_CR45","unstructured":"U.S. Food and Drug Administration. CILOXAN\u00ae (ciprofloxacin HCl) Ophthalmic Solution 0.3% \u2014 Prescribing Information. Silver Spring, MD (2006). Prescribing Information."},{"key":"30598_CR46","unstructured":"U.S. Food and Drug Administration. TOBREX\u00ae (tobramycin ophthalmic solution) 0.3% \u2014 Prescribing Information. Silver Spring, MD (2020). Prescribing Information."},{"key":"30598_CR47","unstructured":"U.S. Food and Drug Administration. OCUFLOX\u00ae (ofloxacin ophthalmic solution) 0.3% \u2014 Prescribing Information. Silver Spring, MD (2016). Prescribing Information."},{"key":"30598_CR48","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ijantimicag.2011.02.013","volume":"38","author":"H-J Tang","year":"2011","unstructured":"Tang, H.-J. et al. In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2\u00b5g\/ml (VA2-MRSA). Int. J. Antimicrob. Agents 38, 46\u201351. https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.02.013 (2011).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"30598_CR49","doi-asserted-by":"crossref","unstructured":"Carr, S. B., Makris, G., Thomas, C. D. & Phillips, S. E. V. Crystal structure of a 59 kDa fragment of topoisomerase IV subunit a (GrlA) from Staphylococcus aureus. New York SGX Research Center for Structural Genomics (2007).","DOI":"10.2210\/pdb2inr\/pdb"},{"key":"30598_CR50","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1021\/cb5001197","volume":"9","author":"J Lu","year":"2014","unstructured":"Lu, J. et al. Structures of kibdelomycin bound to Staphylococcus aureus GyrB and ParE showed a novel U-shaped binding mode. ACS Chem. Biol. 9, 2023-2031. https:\/\/doi.org\/10.1021\/cb5001197 (2014).","journal-title":"ACS Chem. Biol."},{"key":"30598_CR51","unstructured":"DeLano, W.\u00a0L. Pymol: An open-source molecular graphics tool. CCP4 Newsl. protein crystallogr. 40(1), 82\u201392 (2002)."},{"key":"30598_CR52","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/jac\/dkg222","volume":"51","author":"J Ruiz","year":"2003","unstructured":"Ruiz, J. Mechanisms of resistance to quinolones: Target alterations, decreased accumulation, and dna gyrase protection. J. Antimicrob. Chemother. 51, 1109\u20131117 (2003).","journal-title":"J. Antimicrob. Chemother."},{"key":"30598_CR53","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1128\/aac.41.11.2362","volume":"41","author":"M Tanaka","year":"1997","unstructured":"Tanaka, M., Onodera, Y., Uchida, Y., Sato, K. & Hayakawa, I. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob. Agents Chemother. 41, 2362\u20132366. https:\/\/doi.org\/10.1128\/aac.41.11.2362 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30598_CR54","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF chimera\u2014a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612. https:\/\/doi.org\/10.1002\/jcc.20084 (2004).","journal-title":"J. Comput. Chem."},{"key":"30598_CR55","doi-asserted-by":"crossref","unstructured":"Bugnon, M. et al. Swissdock 2024: major enhancements for small-molecule docking with attracting cavities and autodock vina. Nucleic Acids Res. 52(W1), W324\u2013W332 (2024).","DOI":"10.1093\/nar\/gkae300"},{"key":"30598_CR56","doi-asserted-by":"crossref","unstructured":"Eberhardt, J., Santos-Martins, D., Tillack, A. & Forli, S. Autodock vina 1.2.0: New docking methods, expanded force field, and python bindings. J. Chem. Inf. Model. 61(8), 3891\u20133898 (2021).","DOI":"10.1021\/acs.jcim.1c00203"},{"key":"30598_CR57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/1874364101004010052","volume":"4","author":"M Goel","year":"2010","unstructured":"Goel, M., Picciani, R. G., Lee, R. K. & Bhattacharya, S. K. Aqueous humor dynamics: A review. Open Ophthalmol. J. 4, 52\u201359. https:\/\/doi.org\/10.2174\/1874364101004010052 (2010).","journal-title":"Open Ophthalmol. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30598-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30598-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30598-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:19:21Z","timestamp":1781644761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30598-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["30598"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-30598-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15392"}}